Predictors of improved survival for patients with retroperitoneal sarcoma
Background Retroperitoneal sarcomas are rare tumors that can be locally aggressive with high rates of recurrence. Given that data on survival in patients with retroperitoneal sarcomas are conflicting, we sought to use a nationwide cancer database to identify factors associated with survival in patie...
Gespeichert in:
| Veröffentlicht in: | Surgery 2016-12, Vol.160 (6), p.1628-1635 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1635 |
|---|---|
| container_issue | 6 |
| container_start_page | 1628 |
| container_title | Surgery |
| container_volume | 160 |
| creator | Giuliano, Katherine, MD Nagarajan, Neeraja, MD, MPH Canner, Joseph K., MHS Wolfgang, Christopher L., MD, MS, PhD Bivalacqua, Trinity, MD, PhD Terezakis, Stephanie, MD Herman, Joseph, MD Schneider, Eric B., PhD Ahuja, Nita, MD |
| description | Background Retroperitoneal sarcomas are rare tumors that can be locally aggressive with high rates of recurrence. Given that data on survival in patients with retroperitoneal sarcomas are conflicting, we sought to use a nationwide cancer database to identify factors associated with survival in patients with retroperitoneal sarcomas. Methods The Surveillance, Epidemiology, and End Results database was utilized to identify patients with retroperitoneal sarcomas from 2002 to 2012. Univariable and multivariable survival analysis was performed using a generalized gamma parametric survival function. Results A total of 2,920 patients were included; overall 5- and 10-year survivals were 58.4% and 45.3%, respectively. On multivariable survival analysis, age, histologic type, grade, size, local extension, lymph node, and distant metastasis were associated with decreased survival (all P |
| doi_str_mv | 10.1016/j.surg.2016.05.041 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1842535096</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0039606016302380</els_id><sourcerecordid>1842535096</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-fe9da07d47e968a865f6b34f382a54da650f1bcc4d27f36ad8136363502840983</originalsourceid><addsrcrecordid>eNp9kU2L1TAUhoMoznX0D7iQLt20nnw2BRFk8GNgQEFdh9zkVHNtm2uS3mH-vSl3dOFCskgWz_uS8xxCnlPoKFD16tDlNX3vWH13IDsQ9AHZUclZ23NFH5IdAB9aBQouyJOcDwAwCKofkwvWi0FqCTty_TmhD67ElJs4NmE-pnhC39TmUzjZqRljao62BFxKbm5D-dEkLCkeMYUSF6xEtsnF2T4lj0Y7ZXx2f1-Sb-_ffb362N58-nB99famdYLS0o44eAu9Fz0OSlut5Kj2XIxcMyuFt0rCSPfOCc_6kSvrNeWqHglMCxg0vyQvz731p79WzMXMITucJrtgXLOhWjBZ8UFVlJ1Rl2LOCUdzTGG26c5QMJtCczCbQrMpNCBNVVhDL-771_2M_m_kj7MKvD4DWKc8BUwmu6rHVY8JXTE-hv_3v_kn7qawBGenn3iH-RDXtFR_hprMDJgv2xK3HVLFgXEN_Deyrpea</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1842535096</pqid></control><display><type>article</type><title>Predictors of improved survival for patients with retroperitoneal sarcoma</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Giuliano, Katherine, MD ; Nagarajan, Neeraja, MD, MPH ; Canner, Joseph K., MHS ; Wolfgang, Christopher L., MD, MS, PhD ; Bivalacqua, Trinity, MD, PhD ; Terezakis, Stephanie, MD ; Herman, Joseph, MD ; Schneider, Eric B., PhD ; Ahuja, Nita, MD</creator><creatorcontrib>Giuliano, Katherine, MD ; Nagarajan, Neeraja, MD, MPH ; Canner, Joseph K., MHS ; Wolfgang, Christopher L., MD, MS, PhD ; Bivalacqua, Trinity, MD, PhD ; Terezakis, Stephanie, MD ; Herman, Joseph, MD ; Schneider, Eric B., PhD ; Ahuja, Nita, MD</creatorcontrib><description>Background Retroperitoneal sarcomas are rare tumors that can be locally aggressive with high rates of recurrence. Given that data on survival in patients with retroperitoneal sarcomas are conflicting, we sought to use a nationwide cancer database to identify factors associated with survival in patients with retroperitoneal sarcomas. Methods The Surveillance, Epidemiology, and End Results database was utilized to identify patients with retroperitoneal sarcomas from 2002 to 2012. Univariable and multivariable survival analysis was performed using a generalized gamma parametric survival function. Results A total of 2,920 patients were included; overall 5- and 10-year survivals were 58.4% and 45.3%, respectively. On multivariable survival analysis, age, histologic type, grade, size, local extension, lymph node, and distant metastasis were associated with decreased survival (all P < .05). Patients undergoing operative resection survived 2.5 times longer (95% confidence interval: 2.0–3.0, P < .001) and those receiving radiation therapy 1.3 times longer (95% confidence interval: 1.1–1.6, P = .001), respectively. Conclusion During the past decade, retroperitoneal sarcoma patients treated with radiation demonstrate longer survival compared with patients who did not receive radiation. Further study is needed to fully elucidate the mechanisms that underlie the radiation-related survival benefit observed in this study.</description><identifier>ISSN: 0039-6060</identifier><identifier>EISSN: 1532-7361</identifier><identifier>DOI: 10.1016/j.surg.2016.05.041</identifier><identifier>PMID: 27495850</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Combined Modality Therapy ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Retroperitoneal Neoplasms - mortality ; Retroperitoneal Neoplasms - pathology ; Retroperitoneal Neoplasms - therapy ; Retrospective Studies ; Sarcoma - mortality ; Sarcoma - pathology ; Sarcoma - therapy ; SEER Program ; Surgery ; Survival Analysis ; Survival Rate ; United States - epidemiology</subject><ispartof>Surgery, 2016-12, Vol.160 (6), p.1628-1635</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-fe9da07d47e968a865f6b34f382a54da650f1bcc4d27f36ad8136363502840983</citedby><cites>FETCH-LOGICAL-c411t-fe9da07d47e968a865f6b34f382a54da650f1bcc4d27f36ad8136363502840983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.surg.2016.05.041$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27495850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giuliano, Katherine, MD</creatorcontrib><creatorcontrib>Nagarajan, Neeraja, MD, MPH</creatorcontrib><creatorcontrib>Canner, Joseph K., MHS</creatorcontrib><creatorcontrib>Wolfgang, Christopher L., MD, MS, PhD</creatorcontrib><creatorcontrib>Bivalacqua, Trinity, MD, PhD</creatorcontrib><creatorcontrib>Terezakis, Stephanie, MD</creatorcontrib><creatorcontrib>Herman, Joseph, MD</creatorcontrib><creatorcontrib>Schneider, Eric B., PhD</creatorcontrib><creatorcontrib>Ahuja, Nita, MD</creatorcontrib><title>Predictors of improved survival for patients with retroperitoneal sarcoma</title><title>Surgery</title><addtitle>Surgery</addtitle><description>Background Retroperitoneal sarcomas are rare tumors that can be locally aggressive with high rates of recurrence. Given that data on survival in patients with retroperitoneal sarcomas are conflicting, we sought to use a nationwide cancer database to identify factors associated with survival in patients with retroperitoneal sarcomas. Methods The Surveillance, Epidemiology, and End Results database was utilized to identify patients with retroperitoneal sarcomas from 2002 to 2012. Univariable and multivariable survival analysis was performed using a generalized gamma parametric survival function. Results A total of 2,920 patients were included; overall 5- and 10-year survivals were 58.4% and 45.3%, respectively. On multivariable survival analysis, age, histologic type, grade, size, local extension, lymph node, and distant metastasis were associated with decreased survival (all P < .05). Patients undergoing operative resection survived 2.5 times longer (95% confidence interval: 2.0–3.0, P < .001) and those receiving radiation therapy 1.3 times longer (95% confidence interval: 1.1–1.6, P = .001), respectively. Conclusion During the past decade, retroperitoneal sarcoma patients treated with radiation demonstrate longer survival compared with patients who did not receive radiation. Further study is needed to fully elucidate the mechanisms that underlie the radiation-related survival benefit observed in this study.</description><subject>Aged</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Retroperitoneal Neoplasms - mortality</subject><subject>Retroperitoneal Neoplasms - pathology</subject><subject>Retroperitoneal Neoplasms - therapy</subject><subject>Retrospective Studies</subject><subject>Sarcoma - mortality</subject><subject>Sarcoma - pathology</subject><subject>Sarcoma - therapy</subject><subject>SEER Program</subject><subject>Surgery</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><subject>United States - epidemiology</subject><issn>0039-6060</issn><issn>1532-7361</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2L1TAUhoMoznX0D7iQLt20nnw2BRFk8GNgQEFdh9zkVHNtm2uS3mH-vSl3dOFCskgWz_uS8xxCnlPoKFD16tDlNX3vWH13IDsQ9AHZUclZ23NFH5IdAB9aBQouyJOcDwAwCKofkwvWi0FqCTty_TmhD67ElJs4NmE-pnhC39TmUzjZqRljao62BFxKbm5D-dEkLCkeMYUSF6xEtsnF2T4lj0Y7ZXx2f1-Sb-_ffb362N58-nB99famdYLS0o44eAu9Fz0OSlut5Kj2XIxcMyuFt0rCSPfOCc_6kSvrNeWqHglMCxg0vyQvz731p79WzMXMITucJrtgXLOhWjBZ8UFVlJ1Rl2LOCUdzTGG26c5QMJtCczCbQrMpNCBNVVhDL-771_2M_m_kj7MKvD4DWKc8BUwmu6rHVY8JXTE-hv_3v_kn7qawBGenn3iH-RDXtFR_hprMDJgv2xK3HVLFgXEN_Deyrpea</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Giuliano, Katherine, MD</creator><creator>Nagarajan, Neeraja, MD, MPH</creator><creator>Canner, Joseph K., MHS</creator><creator>Wolfgang, Christopher L., MD, MS, PhD</creator><creator>Bivalacqua, Trinity, MD, PhD</creator><creator>Terezakis, Stephanie, MD</creator><creator>Herman, Joseph, MD</creator><creator>Schneider, Eric B., PhD</creator><creator>Ahuja, Nita, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161201</creationdate><title>Predictors of improved survival for patients with retroperitoneal sarcoma</title><author>Giuliano, Katherine, MD ; Nagarajan, Neeraja, MD, MPH ; Canner, Joseph K., MHS ; Wolfgang, Christopher L., MD, MS, PhD ; Bivalacqua, Trinity, MD, PhD ; Terezakis, Stephanie, MD ; Herman, Joseph, MD ; Schneider, Eric B., PhD ; Ahuja, Nita, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-fe9da07d47e968a865f6b34f382a54da650f1bcc4d27f36ad8136363502840983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Retroperitoneal Neoplasms - mortality</topic><topic>Retroperitoneal Neoplasms - pathology</topic><topic>Retroperitoneal Neoplasms - therapy</topic><topic>Retrospective Studies</topic><topic>Sarcoma - mortality</topic><topic>Sarcoma - pathology</topic><topic>Sarcoma - therapy</topic><topic>SEER Program</topic><topic>Surgery</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giuliano, Katherine, MD</creatorcontrib><creatorcontrib>Nagarajan, Neeraja, MD, MPH</creatorcontrib><creatorcontrib>Canner, Joseph K., MHS</creatorcontrib><creatorcontrib>Wolfgang, Christopher L., MD, MS, PhD</creatorcontrib><creatorcontrib>Bivalacqua, Trinity, MD, PhD</creatorcontrib><creatorcontrib>Terezakis, Stephanie, MD</creatorcontrib><creatorcontrib>Herman, Joseph, MD</creatorcontrib><creatorcontrib>Schneider, Eric B., PhD</creatorcontrib><creatorcontrib>Ahuja, Nita, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giuliano, Katherine, MD</au><au>Nagarajan, Neeraja, MD, MPH</au><au>Canner, Joseph K., MHS</au><au>Wolfgang, Christopher L., MD, MS, PhD</au><au>Bivalacqua, Trinity, MD, PhD</au><au>Terezakis, Stephanie, MD</au><au>Herman, Joseph, MD</au><au>Schneider, Eric B., PhD</au><au>Ahuja, Nita, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of improved survival for patients with retroperitoneal sarcoma</atitle><jtitle>Surgery</jtitle><addtitle>Surgery</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>160</volume><issue>6</issue><spage>1628</spage><epage>1635</epage><pages>1628-1635</pages><issn>0039-6060</issn><eissn>1532-7361</eissn><abstract>Background Retroperitoneal sarcomas are rare tumors that can be locally aggressive with high rates of recurrence. Given that data on survival in patients with retroperitoneal sarcomas are conflicting, we sought to use a nationwide cancer database to identify factors associated with survival in patients with retroperitoneal sarcomas. Methods The Surveillance, Epidemiology, and End Results database was utilized to identify patients with retroperitoneal sarcomas from 2002 to 2012. Univariable and multivariable survival analysis was performed using a generalized gamma parametric survival function. Results A total of 2,920 patients were included; overall 5- and 10-year survivals were 58.4% and 45.3%, respectively. On multivariable survival analysis, age, histologic type, grade, size, local extension, lymph node, and distant metastasis were associated with decreased survival (all P < .05). Patients undergoing operative resection survived 2.5 times longer (95% confidence interval: 2.0–3.0, P < .001) and those receiving radiation therapy 1.3 times longer (95% confidence interval: 1.1–1.6, P = .001), respectively. Conclusion During the past decade, retroperitoneal sarcoma patients treated with radiation demonstrate longer survival compared with patients who did not receive radiation. Further study is needed to fully elucidate the mechanisms that underlie the radiation-related survival benefit observed in this study.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27495850</pmid><doi>10.1016/j.surg.2016.05.041</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0039-6060 |
| ispartof | Surgery, 2016-12, Vol.160 (6), p.1628-1635 |
| issn | 0039-6060 1532-7361 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1842535096 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Aged Combined Modality Therapy Female Humans Male Middle Aged Neoplasm Grading Neoplasm Staging Retroperitoneal Neoplasms - mortality Retroperitoneal Neoplasms - pathology Retroperitoneal Neoplasms - therapy Retrospective Studies Sarcoma - mortality Sarcoma - pathology Sarcoma - therapy SEER Program Surgery Survival Analysis Survival Rate United States - epidemiology |
| title | Predictors of improved survival for patients with retroperitoneal sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T08%3A18%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20improved%20survival%20for%20patients%20with%20retroperitoneal%20sarcoma&rft.jtitle=Surgery&rft.au=Giuliano,%20Katherine,%20MD&rft.date=2016-12-01&rft.volume=160&rft.issue=6&rft.spage=1628&rft.epage=1635&rft.pages=1628-1635&rft.issn=0039-6060&rft.eissn=1532-7361&rft_id=info:doi/10.1016/j.surg.2016.05.041&rft_dat=%3Cproquest_cross%3E1842535096%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1842535096&rft_id=info:pmid/27495850&rft_els_id=S0039606016302380&rfr_iscdi=true |